Real-World Safety and Effectiveness of Up to 12 Months of Tralokinumab Treatment in Adults With Atopic Dermatitis Who Discontinued Dupilumab Due to Conjunctivitis

Main Article Content

April Armstrong
University of California Los Angeles, David Geffen School of Medicine, Division of Dermatology, Department of Medicine, Los Angeles, California, United States

Cory Rubin
Michigan Dermatology Institute, Waterford, Michigan, United States

Silvia Ferruci
Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Dermatology Unit, Milan, Italy

Pierre-Andre Becherel
Dermatology and Clinical Immunology Unit, Antony Hospital, Antony, France

Jose Juan Pereyra Rodriguez
Virgen del Rocio University Hospital, Department of Dermatology, Sevilla, Spain; University of Sevilla, Department of Medicine, School of Medicine, Sevilla, Spain

Marni C Wiseman
SKiNWISE DERMATOLOGY, Winnipeg, Manitoba, Canada; Section of Dermatology, Department of Medicine, University of Manitoba, Manitoba, Canada

Ahmed Ameen
NMC Specialty Hospital, Abu Dhabi, United Arab Emirates

Teodora Festini
LEO Pharma A/S, Ballerup, Denmark

Frank Vinther
LEO Pharma A/S, Ballerup, Denmark

Ida Vittrup
LEO Pharma A/S, Ballerup, Denmark

Diamant Thaçi
Institute and Comprehensive Center for Inflammation Medicine, University of Lübeck, Lübeck, Germany

Keywords

real-world, safety, effectiveness, tralokinumb, Conjunctivitis

Abstract

N/A

References

N/A

Article Sidebar

PDF
Published
2026-03-10
DOI: https://doi.org/10.25251/1jtrf706

Article Details

How to Cite
1.
Real-World Safety and Effectiveness of Up to 12 Months of Tralokinumab Treatment in Adults With Atopic Dermatitis Who Discontinued Dupilumab Due to Conjunctivitis. J of Skin. 2026;10(2):s729. doi:10.25251/1jtrf706
Issue
Vol. 10 No. 2 (2026): March 2026 Issue
Section
Poster Presentations at 2026 Winter Clinical Dermatology Conference®: Atopic Dermatitis
Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

All authors retain copyright in their articles. All articles published open access allowing for immediate free access to the work and permitting any user to read, download, copy, distribute, print, search, or link to the full texts of articles, crawl them for indexing, pass them as data to software or use them for any other lawful purpose. Permitted reuse is defined by  the following user license:
 

Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation. 

Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.ca/ojs/.

Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.

Most read articles by the same author(s)

1 2 3 4 5 6 7 8 9 10 > >>